
Institute of Child Health and
Human Development
and the
NIH Clinical Center

Clinical Research
Clinical Care
Clinical Training


- Warren Grant Magnuson Clinical Center
- Mark O. Hatfield Clinical Research Center (2005)
 - 240 Beds (22 Pediatric)
 - 10,700 new patients
 - 5,400 inpatients
 - 100,500 outpatients




- NICHD Clinical Protocols
 - 85 Protocols
 - 36 Principal Investigators
 - 14 Senior Investigators
 - 6 Staff Clinicians
 - 122 Associate Investigators
- Endocrinology
 - Pediatric
 - Adult
 - Reproductive
- Genetics



NICHD Patients/Subjects






NICHD Patient/Subjects

Inpatient days2449

Outpatient visits 5080

Adjusted Patient Days 4481




- Office of the Clinical Director: Research Support
 - Staff Clinicians
 - 2 Internal Medicine
 - 3 Pediatric (2 Additional Pending)
 - 2 Gynecology
 - Nurse Practitioners
 - 3 Pediatric
 - 1 Family
 - 1 Adult
 - Research Nurses/Research Coordinators (4)


- Bench-To-Bedside Award Program (1999)
 - \$135,000 direct costs for two years
 - Increased to \$150,000 for 2017
 - Competitive awards
- Criteria
 - Utilize the NIH Clinical Center
 - Basic/clinical collaboration
 - Intramural/extramural collaboration (2006)



Bench-to-Bedside Awards by Lead Institute 2006 – 2015



- AIDS
- Behavioral and Social Sciences
- Dietary Supplements
- Minority Health
- Rare Diseases
- Women's Health Projects



- 17 Investigators/Senior Investigators
 - 2 Associate Clinical Investigators
 - 3 Staff Clinicians
 - 6 Staff Scientists

- U01 Grants: Opportunities for Collaborative Research at the NIH Clinical Center
 - Supports collaborative research to enhance the translation of basic biological discoveries into clinical applications that improve health
 - Extramural/Intramural/Clinical Center
 - \$500,000 direct costs, 3 years (now 4 years)

LOIs/X02s	CYCLE 1 2013	CYCLE 2 2014	CYCLE 3 2015	CYCLE 4 2016
Submissions	74	44	47	54
Applications	51	33	36	40
Resubmissions	N/A	14	6	10
Awards	10	10	3*	
Success Rate	20%	30%	8%	

Funding IC	Cycle 1	Cycle 2	Cycle 3
NCI	3	1	1
NHLBI	1	2	1
NIAID	4	3	1
NICHD	2	2	
NHGRI		1	
NIAAA		1	

- A Phase 1 Dose Escalation Study of Vorinostat in Niemann-Pick C1
 Disease
- Birth Defects: Moebius Syndrome and Related Facial Weakness Disorders
- Antiretroviral Therapy in Aicardi Goutieres Syndrome
- Choroid Plexus-Directed Gene Therapy for Alpha-Mannosidosis

- Weill Medical College
- Washington University
- Icahn School of Medicine
- Boston Children's Hospital
- National Children's Hospital
- Children's Hospital of Philadelphia


- NHGRI
- NEI
- NINDS
- Clinical Center

- Pediatric Endocrinology Inter-Institute Training Program
 - Clinical Sites
 - NIH Clinical Center
 - Children's National Medical Center
 - Johns Hopkins Medical Center
 - Georgetown University
 - Three fellows per year
- Inter-Institute Endocrine Training Program
 - Clinical Sites
 - NIH Clinical Center
 - Georgetown University
 - Washington Hospital Center
 - Five fellows per year (2 NICHD, 3 NIDDK)

- Reproductive Endocrinology and Infertility Training Program
 - Clinical Sites
 - NIH Clinical Center
 - Shady Grove Fertility Center
 - Walter Reed National Military Medical Center
 - Three fellows per year
- Medical Genetics Training Program
 - Program in NHGRI/Johns Hopkins
 - Faculty and Fellowship Executive Board

Section on Genetics and Endocrinology

Adrenal Tumors/Hyperplasia: "Omics Approach" WG/ES, CGH, CNV, RNAseq, methylation



ARMC5 gene: N Engl J Med. 2013;369:2105

PRKACA gene: N Engl J Med. 2014;370:1019

PRKACB gene: N Engl J Med. 2014;370:1065


Section on Genetics and Endocrinology

The NEW ENGLAND JOURNAL of MEDICINE

ORIGINAL ARTICLE

Gigantism and Acromegaly Due to Xq26 Microduplications and *GPR101* Mutation


G. Trivellin, A.F. Daly, F.R. Faucz, B. Yuan, L. Rostomyan, D.O. Larco, M.H. Schernthaner-Reiter, E. Szarek, L.F. Leal, J.-H. Caberg, E. Castermans, C. Villa, A. Dimopoulos, P. Chittiboina, P. Xekouki, N. Shah, D. Metzger, P.A. Lysy, E. Ferrante, N. Strebkova, N. Mazerkina, M.C. Zatelli, M. Lodish, A. Horvath, R. Bertollo de Alexandre, A.D. Manning, I. Levy, M.F. Keil, M. de la Luz Sierra, L. Palmeira, W. Coppieters, M. Georges, L.A. Naves, M. Jamar, V. Bours, T.J. Wu, C.S. Choong, J. Bertherat, P. Chanson, P. Kamenický, W.E. Farrell, A. Barlier, M. Quezado, I. Bjelobaba, S.S. Stojilkovic, J. Wess, S. Costanzi, P. Liu, J.R. Lupski, A. Beckers, and C.A. Stratakis



Section on Growth and Development

Exome sequencing identifies ACAN mutations in AD short stature





Aggrecan: Proteoglcycan in cartilage matix
Short stature
Advance bone age
Joint disease
Nilsso


Nilsson et al. (2014) JCEM 99: E1510-18

Section on Growth and Obesity


- RCT of effects of a low glycemic load or a low-fat dietary intervention on body weight in obese Hispanic American children and adolescents.
 Am J Clin Nutr 97(2): 276-85, 2013
- RCT of Effects of Interrupting Sedentary Behavior on Metabolic and Cognitive Outcomes in Children. JCEM 100: 3735-3743, 2015
- RCT of effects of metformin on body weight, food Intake and satiety in obese children. Diabetes 60:477-85, 2011; Diabetes Obes Metab 17:363-370, 2015
- RCT for excess weight gain prevention in adolescents: one and three-year outcomes. Am J Clin Nutr 100: 1010-1018, 2014; Int J Eat Disord 49: 490-498, 2016;
 - In Press, J Consult Clin Psych
- RCT to prevent depression and ameliorate insulin resistance in adolescent girls at-risk for Type 2 Diabetes. In Press, Ann Behav Med
- Niacin to suppress lipolysis in children with obesity. In press, Pediatr Obes

Section on Medical Neuroendocrinology

Pheochromocytoma and Paraganglioma



⁶⁸Ga-DOTATATE PET: novel functional imaging for SDHB-related metastatic PHEO/PGLs and HNPGL




Overall detection rate 98.6%

Janssen et al. Clin. Cancer Res. 2015; 21:3888

Section on Molecular Dysmorphology

Phase 1/2a trial of 2-hydroxypropyl-β-cyclodextrin for the treatment of Niemann-Pick Disease, type C1



- NCATS pilot project
- FDA breakthrough designation
- Multicenter, multinational Phase 2b/3 trial

Thank you